SCHEMBL4499534

SCHEMBL4499534

c1cc2nccnn2c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL46494 0.80
SCHEMBL19173 0.80
Water SCHEMBL29860131 0.78 DYRK1A (0.41)
SCHEMBL31338725 0.78 PDE10A (0.45)
Hydrochloric Acid SCHEMBL30128120 0.78 DYRK1A (0.41)
SCHEMBL3962541 0.78 DYRK1A (0.41)
SCHEMBL31674379 0.78 PDE10A (0.45)
Hydrochloric Acid SCHEMBL6894527 0.78 PDE10A (0.45)
SCHEMBL31237159 0.78 DYRK1A (0.41)
Iodide SCHEMBL9950363 0.78 DYRK1A (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1115710-A1 PROCESS FOR PREPARING REGIOSPECIFIC SUBSTITUTED PYRAZINE ISOMERS ABBOTT LABORATORIES (US) 2001-07-18 EP claimed
WO-2000010983-A1 PROCESS FOR PREPARING REGIOSPECIFIC SUBSTITUTED PYRAZINE ISOMERS ABBOTT LABORATORIES (US) 2000-03-02 WO claimed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
US-20230144197-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2023-05-11 US disclosed
US-20230144197-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2023-05-11 US disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 EP disclosed
US-11197857-B2 Combination therapy GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-12-14 US disclosed
US-11185531-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2021-11-30 US disclosed
WO-2021122745-A1 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2021-06-24 WO disclosed
US-20210106580-A1 COMBINATION THERAPY GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-15 US disclosed
US-20210078951-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. 2021-03-18 US disclosed
US-20090286796-A1 Compounds exhibiting type X sPLA2 inhibiting effect OGAWA TOMOYUKI 2009-11-19 US disclosed
US-20090134780-A1 Electron transport material and organic electroluminescent device using the same SK MATERIALS JNC CO., LTD. (KR) 2009-05-28 US disclosed
US-20090134780-A1 Electron transport material and organic electroluminescent device using the same SK MATERIALS JNC CO., LTD. (KR) 2009-05-28 US disclosed
US-20060116379-A1 Compounds exhibiting type X sPLA2 inhibiting effect OGAWA TOMOYUKI 2006-06-01 US disclosed
US-7026318-B2 Compounds exhibiting X-type sPLA2 inhibiting effect SHIONOGI & CO., LTD. (JP) 2006-04-11 US disclosed
US-20030181454-A1 Compounds exhibiting x-type spla2 inibiting effect SHIONOGI & CO., LTD. (JP) 2003-09-25 US disclosed
EP-1115710-A1 PROCESS FOR PREPARING REGIOSPECIFIC SUBSTITUTED PYRAZINE ISOMERS ABBOTT LABORATORIES (US) 2001-07-18 EP disclosed
CN-1304410-A Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them ASTRA ZENECA LTD (SE) 2001-07-18 CN disclosed
WO-2000010983-A1 PROCESS FOR PREPARING REGIOSPECIFIC SUBSTITUTED PYRAZINE ISOMERS ABBOTT LABORATORIES (US) 2000-03-02 WO disclosed